Maxwell D. Janosky, MD

Insurances Accepted

Please contact your insurance company directly prior to receiving services or care to confirm your coverage. Although we have made every effort to ensure this list is accurate, only your health insurance plan can provide complete information regarding your coverage and potential out-of-pocket costs.

About Maxwell Janosky

Dr. Janosky is board certified in internal medicine, hematology, and oncology. A member of the Englewood Health Physician Network, he specializes in blood disorders, blood cancer, brain cancer, head and neck cancer, endocrine cancer, dermatological cancer, and gynecological cancer. He has also practiced as a leukemia and lymphoma hospitalist. Dr. Janosky has particular interest in biologic agents, cancer prevention, chemotherapy, hereditary cancer predisposition, immunologic approaches, and pain management and palliative care. After receiving his MD from Loma Linda University, he did an internal medicine residency at the University of California, San Francisco, and a hematology/oncology fellowship at New York University. He participates in clinical trials, as well as an ongoing basic science project on matrix metalloproteinase inhibition for the prevention of breast cancer metastasis.

Honors & Awards

2020, 2019: Bergen Magazine Top Doctors

2020, 2019: Castle Connolly Top Doctor New York Metro Area

2020, 2019: Castle Connolly Regional Top Doctor

2019: Jersey's Best Magazine Top Doctor

2014: Franco Muggia Clinical Trials Award, New York University

Professional Memberships

American Society of Hematology

American Society of Clinical Oncology

Committees and Leadership Positions

Medicine Professional Practice Committee, Department of Hematology and Oncology

VTE Committee

2009-2010: Mentor, Residency Diversity Committee Mentorship Program, University of California, San Francisco

Global Health and Community Health Activities

2017: A Community Conversation on Prostate Cancer Education

Publications

Winer A, Janosky M, Harrison B, Zhong J, Moussai D, Siyah P, Schatz-Siemers N, Zeng J, Adams S, Mignatti P. Inhibition of Breast Cancer Metastases by Presurgical Treatment with an Oral Matrix Mettaloproteinase Inhibitor: A Preclinical Proof-of-Principle Study. Molecular Cancer Therapeutics. July 27 2016. 15 (10): 2370-2377.

Janosky M, Bian J, Dhage S, Levine J, Silverman J, Jors K, Moy L, Cangiarella J, Muggia F, Adams S. Primary Large Cell Neuroendocrine Carcinoma of the Breast, a Case Report with an Unusual Clinical Course. Breast Journal. 2015 May. 21 (3): 303-307.

Janosky M, Sabado RL, Cruz C, Vengco I, Hasan F, Winer A, Moy L, Adams S. MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy. Journal for Immunotherapy of Cancer 2014, 2:32.

Janosky M, Bian J, Dhage S, Levine J, Silverman J, Jors K, Moy L, Cangiarella J, Muggia F, Adams S. Primary Large Cell Neuroendocrine Carcinoma of the Breast, a case report with an unusual clinical course. The Breast Journal, 21(2): 2015.

Janosky M, Sabado R, Cruz C, Vengco I, Hasan F, Adams S. Ex-vivo detectable Mage-specific T cells correlate with complete remission in metastatic breast cancer patients after sequential immuno-endocrine therapy. Journal of Immunotherapy, 2012. 35(9): p. 730.

Daud A, Janosky M, Dubey S. Adjuvant Therapy in Melanoma: New Combination Cytokine, and Other Strategies. Medscape Review. 2008.

Rugo H, Carey L, Janosky M. Emerging Therapeutic Options for Patients with ER/PR/HER2-Negative Metastatic Breast Cancer. “The Oncologist”